Page 7 - வீரியம்+மிக்கது கட்டி ஆஃப் மார்பக News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வீரியம்+மிக்கது கட்டி ஆஃப் மார்பக. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வீரியம்+மிக்கது கட்டி ஆஃப் மார்பக Today - Breaking & Trending Today

Things to do today in Bengaluru

Lahe Lahe, ABCs, vigour, melodious tunes, DJ Nash ....

Melodious Tunes , Dj Nash , ட்ஜ் நஷ் ,

New Automatic Balance Improves Dosing Accuracy, Productivity and Safety

Today’s laboratories are handling higher throughput and smaller sample sizes than ever before. Click to read more. ....

Synairgen plc: Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients


Synairgen plc: Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
( Synairgen or the Company )
Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
Southampton, UK - 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled interferon beta formulation (SNG001) sub-study of the ACTIV-2 Phase II/III trial, evaluating patients with mild to moderate COVID-19 symptoms not yet requiring hospitalisation.
Richard Marsden, CEO of Synairgen, said: ....

United Kingdom , Olivia Manser , Geoff Nash , Richard Marsden , John Ward , Donna Davies , James Thompson , Duncan Monteith , James Black , Mary Jane Elliott , Ratko Djukanovic , Freddie Barnfield , Numis Securities Limited Joint Broker , University Of Southampton Professors Sir Stephen Holgate , National Institute Of Allergy , National Institutes Of Health , Clinical Trials Group , Consilium Strategic Communications Financial Media , National Institute , Infectious Diseases , National Institutes , Trials Group , Market Abuse Regulation , Chief Executive , Nominated Advisor , Joint Broker ,